Prior adherence to recommended lipid control targets in patients admitted for acute coronary syndrome.
Acute Coronary Syndrome
/ blood
Aged
Anticholesteremic Agents
/ administration & dosage
Cholesterol, LDL
/ blood
Dyslipidemias
/ drug therapy
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Lipids
/ blood
Male
Medication Adherence
Middle Aged
Risk Factors
Treatment Outcome
Acute coronary syndrome
Cardiovascular risk
Cholesterol
Colesterol
Estatinas
Lipids
Lípidos
Riesgo cardiovascular
Statins
Síndrome coronario agudo
Journal
Revista espanola de cardiologia (English ed.)
ISSN: 1885-5857
Titre abrégé: Rev Esp Cardiol (Engl Ed)
Pays: Spain
ID NLM: 101587954
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
08
02
2019
accepted:
13
06
2019
pubmed:
11
11
2019
medline:
31
3
2021
entrez:
11
11
2019
Statut:
ppublish
Résumé
Optimal lipid control is difficult to attain. We assessed preadmission achievement of the European Society of Cardiology targets for low-density lipoprotein-cholesterol (LDL-C) control in patients admitted for acute coronary syndrome. Fasting LDL-C levels were measured in 3164 patients admitted between 2010 and 2017. We assessed the frequency of adequate LDL-C control, with targets defined according to individual cardiovascular risk, and the predictors of inadequate control. The median LDL-C value was 104 (80-130) mg/dL. Most patients had high or very high cardiovascular risk and only 34.2% had LDL-C levels below the recommended target for their estimated risk. Achievement of LDL-C goals increased moderately throughout the study period. Adequate LDL-C control was inversely associated with patient risk. Dyslipidemia, active smoking, diabetes mellitus, and body mass index ≥ 25 were independent predictors of inadequate lipid control, while ongoing statin therapy was associated with adequate control. Only slightly more than one third of patients admitted for acute coronary syndrome meet recommended LDL-C targets on admission. There is broad scope for improvement in primary and secondary prevention, especially among patients who are overweight or have other cardiovascular risk factors.
Identifiants
pubmed: 31706709
pii: S1885-5857(19)30293-2
doi: 10.1016/j.rec.2019.06.014
pii:
doi:
Substances chimiques
Anticholesteremic Agents
0
Cholesterol, LDL
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Lipids
0
Types de publication
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
376-382Informations de copyright
Copyright © 2019 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.